- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07491952
Continue Dubbele Aspiratie Techniek Met Zoom Systeem voor Beroerte (ADAPT 2 0)
Klinische evaluatie van de continue dubbele aspiratietechniek met het Zoom-systeem voor beroerte (ADAPT 2.0)
This study is designed to evaluate the effectiveness, safety and clinical performance of ADAPT 2.0, first-line aspiration neurothrombectomy with Zoom System with Continuous Dual Aspiration Technique (CDAT).
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Pojai Phattanagosai
- Telefoonnummer: 650-740-7703
- E-mail: pphattanagosai@Imperativecare.com
Studie Contact Back-up
- Naam: Emma Pham
- Telefoonnummer: 408-421-7684
- E-mail: epham@imperativecare.com
Studie Locaties
-
-
Alabama
-
Huntsville, Alabama, Verenigde Staten, 35801
- Werving
- Huntsville Hospital
-
Contact:
- Farrar Hickey
-
Hoofdonderzoeker:
- R. Dana Tomalty, MD
-
-
California
-
Walnut Creek, California, Verenigde Staten, 94598
- Werving
- John Muir Health
-
Hoofdonderzoeker:
- Benjamin Yim, MD
-
Contact:
- Melenie Aaron
-
-
Florida
-
Tampa, Florida, Verenigde Staten, 33606
- Werving
- University of South Florida
-
Hoofdonderzoeker:
- Maxim Mokin, MD
-
Contact:
- Kilaun Robinson
-
-
Georgia
-
Marietta, Georgia, Verenigde Staten, 30060
- Werving
- Wellstar Kennestone Hospital
-
Contact:
- Autumn Lee
-
Hoofdonderzoeker:
- Ahmad Khaldi, MD
-
-
Louisiana
-
Lafayette, Louisiana, Verenigde Staten, 70503
- Werving
- Ochsner Clinic Foundation (Lafayette)
-
Hoofdonderzoeker:
- Shail Thanki, MD
-
New Orleans, Louisiana, Verenigde Staten, 70121
- Werving
- Ochsner Clinic Foundation
-
Hoofdonderzoeker:
- James Milburn, MD
-
Contact:
- Jessica Henry
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21201
- Werving
- University of Maryland
-
Hoofdonderzoeker:
- Jacob Cherian, MD
-
Contact:
- Katie Henry
-
-
Minnesota
-
Minneapolis, Minnesota, Verenigde Staten, 55407
- Werving
- Allina Health
-
Contact:
- Emeryth Beloy
-
Hoofdonderzoeker:
- Collin Torok, MD
-
-
New York
-
Albany, New York, Verenigde Staten, 12208
- Werving
- Albany Medical College
-
Hoofdonderzoeker:
- Alexandra Paul, MD
-
Contact:
- Chelsey Large
-
Buffalo, New York, Verenigde Staten, 14203
- Werving
- University at Buffalo Neurosurgery
-
Hoofdonderzoeker:
- Jason Davies, MD
-
Contact:
- Ellen Carl
-
New York, New York, Verenigde Staten, 10065
- Werving
- Weill Cornell Medicine
-
Contact:
- Hanah Hwang
-
Hoofdonderzoeker:
- Amol Mehta, MD
-
New York, New York, Verenigde Staten, 10029
- Werving
- Icahn School of Medicine at Mount Sinai
-
Contact:
- Kevin Buttet
-
Hoofdonderzoeker:
- Michael T Caton, MD
-
Syracuse, New York, Verenigde Staten, 13210
- Werving
- SUNY Upstate Medical Center
-
Contact:
- Saptarshi Prachi
-
Hoofdonderzoeker:
- Haydn Hoffman, MD
-
The Bronx, New York, Verenigde Staten, 10467
- Werving
- Montefiore Medical Center
-
Contact:
- Genesis Liriano
-
Hoofdonderzoeker:
- Amanda Baker, MD
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten, 45220
- Werving
- TriHealth Good Samaritan Hospital
-
Hoofdonderzoeker:
- Andrew Ringer, MD
-
Contact:
- Mehnaaz Ali
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Verenigde Staten, 73104
- Werving
- University of Oklahoma, Health Science Center
-
Hoofdonderzoeker:
- Hakeem Shakir, MD
-
Contact:
- Sanaa Hameed
-
-
South Carolina
-
Greenville, South Carolina, Verenigde Staten, 29605
- Werving
- Prisma Health - Upstate
-
Contact:
- Shawn Manos
-
Hoofdonderzoeker:
- Jan Vargas Machaj, MD
-
-
Tennessee
-
Knoxville, Tennessee, Verenigde Staten, 37902
- Werving
- Fort Sanders Regional Medical Center
-
Contact:
- Cameron Carter
-
Hoofdonderzoeker:
- Robert Hixson, MD
-
Memphis, Tennessee, Verenigde Staten, 38120
- Werving
- Semmes Murphey Foundation
-
Hoofdonderzoeker:
- Lucas Elijovich, MD
-
Contact:
- Wendell Barnett
-
-
Texas
-
Kingwood, Texas, Verenigde Staten, 77339
- Werving
- HCA Houston Healthcare Kingwood
-
Hoofdonderzoeker:
- Mohamad Ezzeldin, MD
-
Contact:
- Swathi Potla
-
San Antonio, Texas, Verenigde Staten, 78229
- Werving
- Methodist Healthcare System of San Antonio
-
Contact:
- Samantha Franklin
-
Hoofdonderzoeker:
- Lee Birnbaum, MD
-
San Antonio, Texas, Verenigde Staten, 78229
- Werving
- University of Texas Science Health Center at San Antonio
-
Hoofdonderzoeker:
- Justin Mascitelli, MD
-
Contact:
- Athena Lazaris-Conner
-
-
Utah
-
Salt Lake City, Utah, Verenigde Staten, 84112
- Werving
- University of Utah
-
Contact:
- Andrew Grandemange
-
Hoofdonderzoeker:
- Robert Rennert, MD
-
-
Virginia
-
Falls Church, Virginia, Verenigde Staten, 22042
- Werving
- Inova Fairfax Medical Campus
-
Contact:
- Lauren Monroe
-
Hoofdonderzoeker:
- James McEachern, MD
-
-
Washington
-
Spokane, Washington, Verenigde Staten, 99204
- Werving
- Providence Sacred Heart Medical Center and Children's Hospital
-
Contact:
- Kyle Kramer
-
Hoofdonderzoeker:
- Christopher Zylak, MD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Adult subjects with acute ischemic stroke secondary to large vessel occlusion (LVO) meeting the study eligibility criteria and providing written informed consent.
Beschrijving
Inclusion Criteria:
- Subject is ≥ 18 years of age
- Subject or legally authorized representative has provided written informed consent prior to any study-specific procedures and no later than 72 hours after the index procedure
- Pre-stroke mRS 0-2
- Subject is undergoing or has undergone an aspiration thrombectomy using the Zoom System with Continuous Dual Aspiration Technique (CDAT) as the first line device within its intended use
Exclusion Criteria:
- Subjects with a life expectancy of less than 6 months
- Female subject who is known to be pregnant at time of admission
- Any intracranial hemorrhage in the qualifying head CT or MRI
- Presence of tandem internal carotid artery occlusion, multiple occlusion locations (e.g., cavernous ICA and M1, separate M2 occlusions, etc.), or occlusions in multiple territories (e.g., MCA and ACA, bilateral, etc.).
- In the opinion of the Investigator, the patient is not a suitable candidate for intervention with the Zoom System
- Subject is currently enrolled in or planned to be enrolled in any concurrent interventional study that may impact the safety or performance data collected in this study
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: COHORT
- Tijdsperspectieven: PROSPECTIVE
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
ADAPT 2.0: Zoom System with Continuous Dual Aspiration Technique (CDAT)
The Zoom System is intended to be used as the first-line device and utilized within the FDA-cleared indications for use, consistent with the approved labeling and intended anatomical targets. |
Aspiration neurothrombectomy using Zoom System with Continuous Dual Aspiration Technique (CDAT)
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Proportion of patients achieving modified Thrombolysis in Cerebral Infarction (mTICI) score of ≥2c at the end of procedure, as adjudicated by independent core-lab
Tijdsspanne: End of procedure
|
mTICI scale ranges from 0 to 3, with higher scores indicating better reperfusion. mTICI 0: No antegrade reperfusion; mTICI 1: Antegrade reperfusion past initial occlusion, limited distal filling; mTICI 2a: Antegrade reperfusion of less than half (<50%) of the previously occluded target artery's ischemic territory; mTICI 2b: Antegrade reperfusion of more than half (≥50%) of the previously occluded target artery's ischemic territory; mTICI 2c: Near-complete (90-99%) reperfusion, or filling of all distal branches with slower flow; mTICI 3: Complete antegrade reperfusion of all branches |
End of procedure
|
|
Rate of Embolization to New Territory (ENT) on final angiography at the end of the procedure by investigator assessment
Tijdsspanne: End of procedure
|
Embolization to New Territory (ENT), defined as the presence of new occlusions on final angiography that occur in vascular territories remote from those effected by index stroke, as assessed by the investigator |
End of procedure
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Time to achieve mTICI≥2c, defined as groin puncture to investigator assessment for mTICI≥2c
Tijdsspanne: Intraprocedural
|
The time from groin puncture to mTICI (modified treatment in cerebral infarction) score ≥ 2c using study device and technique. mTICI scale ranges from 0 to 3, with higher scores indicating better reperfusion. mTICI 0: No antegrade reperfusion; mTICI 1: Antegrade reperfusion past initial occlusion, limited distal filling; mTICI 2a: Antegrade reperfusion of less than half (<50%) of the previously occluded target artery's ischemic territory; mTICI 2b: Antegrade reperfusion of more than half (≥50%) of the previously occluded target artery's ischemic territory; mTICI 2c: Near-complete (90-99%) reperfusion, or filling of all distal branches with slower flow; mTICI 3: Complete antegrade reperfusion of all branches |
Intraprocedural
|
|
Proportion of cases with clot ingestion, as evidenced by clot captured within the Zoom POD
Tijdsspanne: Intraprocedural
|
Proportion of cases with clot ingestion, as evidenced by clot captured within at least one of the Zoom PODs |
Intraprocedural
|
|
Proportion of cases with clot captured within the Zoom POD connected to the outer aspiration catheter
Tijdsspanne: Intraprocedural
|
Proportion of cases with clot ingestion, as evidenced by clot captured within the outer Zoom PODs |
Intraprocedural
|
|
Rate of rescue therapy
Tijdsspanne: Intraprocedural
|
Proportion of cases with rescue therapy, defined as unplanned use of another manufacturer's thrombectomy device, angioplasty, or stenting within the target vessel territory to achieve mTICI≥2c. |
Intraprocedural
|
|
Rate of functional independence (mRS 0-2) at 90 days
Tijdsspanne: 90 days post-procedure
|
Proportion of patients achieving mRS (modified Rankin Scale) ≤2 at 90 days mRS range: 0 to 6; The mRS scale ranges from 0 (no symptoms) to 5 (severe disability), with an additional category of 6 for death; higher score means worse outcome |
90 days post-procedure
|
|
Proportion of patients achieving First Pass Effect (FPE) mTICI ≥2c as adjudicated by independent core-lab
Tijdsspanne: Intraprocedural
|
Proportion of cases achieving First Pass Effect (FPE), defined as mTICI ≥2c after the first pass with the study device and technique as adjudicated by independent core-lab mTICI scale ranges from 0 to 3, with higher scores indicating better reperfusion. mTICI 0: No antegrade reperfusion; mTICI 1: Antegrade reperfusion past initial occlusion, limited distal filling; mTICI 2a: Antegrade reperfusion of less than half (<50%) of the previously occluded target artery's ischemic territory; mTICI 2b: Antegrade reperfusion of more than half (≥50%) of the previously occluded target artery's ischemic territory; mTICI 2c: Near-complete (90-99%) reperfusion, or filling of all distal branches with slower flow; mTICI 3: Complete antegrade reperfusion of all branches |
Intraprocedural
|
|
Rate of symptomatic intracranial hemorrhage (sICH), as confirmed by imaging and independently adjudicated by medical monitor, at the 24-hour post-procedure
Tijdsspanne: 24-hour post-procedure
|
Independently adjudicated rate of symptomatic intracranial hemorrhage (sICH) defined as any apparently extravascular blood in the brain or within the cranium confirmed by imaging that is associated with clinical deterioration as defined by an increase of four or more points in the NIHSS at 24 hours compared to the baseline assessment, or that led to death, and was judged to be the predominant cause of a neurologic deterioration or death, per ECASS III criteria |
24-hour post-procedure
|
|
90-day all-cause mortality
Tijdsspanne: 90 days post-procedure
|
Rate of all-cause mortality through 90 days post-procedure |
90 days post-procedure
|
|
Rate of device-related Serious Adverse Events, independently adjudicated medical monitor
Tijdsspanne: Intraprocedural
|
Independently adjudicated rate of Serious Adverse Events related to study device |
Intraprocedural
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: David Fiorella, MD, Stony Brook University Hospital
- Hoofdonderzoeker: Shahram Majidi, MD, Icahn School of Medicine at Mount Sinai
- Hoofdonderzoeker: Justin Masciteli, MD, The University of Texas Health Science Center at San Antonio
- Hoofdonderzoeker: Maxim Mokin, MD, University of South Florida
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Cerebrovasculaire aandoeningen
- Hersenziekten
- Ziekten van het centrale zenuwstelsel
- Ziekten van het zenuwstelsel
- Vaatziekten
- Hart-en vaatziekten
- Ischemische beroerte
- Hartinfarct
- Chirurgische procedures, operatief
- Vasculaire chirurgische procedures
- Cardiovasculaire chirurgische procedures
- Trombectomie
Andere studie-ID-nummers
- ICI-2025-003
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .